88 related articles for article (PubMed ID: 8094001)
1. Multicenter, randomized, placebo-controlled study of ditiocarb (Imuthiol) in human immunodeficiency virus-infected asymptomatic and minimally symptomatic patients. The HIV87 Study Group.
AIDS Res Hum Retroviruses; 1993 Jan; 9(1):83-9. PubMed ID: 8094001
[TBL] [Abstract][Full Text] [Related]
2. Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with symptomatic HIV infection and AIDS. A randomized, double-blind, placebo-controlled, multicenter study.
Hersh EM; Brewton G; Abrams D; Bartlett J; Galpin J; Gill P; Gorter R; Gottlieb M; Jonikas JJ; Landesman S
JAMA; 1991 Mar; 265(12):1538-44. PubMed ID: 1671884
[TBL] [Abstract][Full Text] [Related]
3. Biological activity of diethyldithiocarbamate (Ditiocarb, Imuthiol) in an animal model of retrovirus-induced immunodeficiency disease and in clinical trials in patients with HIV infection. The Ditiocarb Study Group.
Hersh EM; Funk CY; Petersen EA; Mosier DE
Dev Biol Stand; 1990; 72():355-63. PubMed ID: 2178128
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
[TBL] [Abstract][Full Text] [Related]
5. Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection.
Lang JM; Touraine JL; Trepo C; Choutet P; Kirstetter M; Falkenrodt A; Herviou L; Livrozet JM; Retornaz G; Touraine F
Lancet; 1988 Sep; 2(8613):702-6. PubMed ID: 2901566
[TBL] [Abstract][Full Text] [Related]
6. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
[TBL] [Abstract][Full Text] [Related]
7. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
[TBL] [Abstract][Full Text] [Related]
8. The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group.
Volberding PA; Lagakos SW; Grimes JM; Stein DS; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS; Phair JP; Mitsuyasu RT
JAMA; 1994 Aug; 272(6):437-42. PubMed ID: 7913730
[TBL] [Abstract][Full Text] [Related]
9. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
Hamilton JD; Hartigan PM; Simberkoff MS; Day PL; Diamond GR; Dickinson GM; Drusano GL; Egorin MJ; George WL; Gordin FM
N Engl J Med; 1992 Feb; 326(7):437-43. PubMed ID: 1346337
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
[TBL] [Abstract][Full Text] [Related]
11. A randomized, controlled dose response study of intravenous sodium diethyldithiocarbamate in patients with advanced human immunodeficiency virus infection.
Kaplan CS; Petersen EA; Yocum D; Hersh EM
Life Sci; 1989; 45(22):iii-ix. PubMed ID: 2557513
[TBL] [Abstract][Full Text] [Related]
12. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.
Choi S; Lagakos SW; Schooley RT; Volberding PA
Ann Intern Med; 1993 May; 118(9):674-80. PubMed ID: 8096373
[TBL] [Abstract][Full Text] [Related]
13. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HIV progression by dithiocarb. German DTC Study Group.
Reisinger EC; Kern P; Ernst M; Bock P; Flad HD; Dietrich M
Lancet; 1990 Mar; 335(8691):679-82. PubMed ID: 1969060
[TBL] [Abstract][Full Text] [Related]
15. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial.
Lane HC; Davey V; Kovacs JA; Feinberg J; Metcalf JA; Herpin B; Walker R; Deyton L; Davey RT; Falloon J
Ann Intern Med; 1990 Jun; 112(11):805-11. PubMed ID: 1971503
[TBL] [Abstract][Full Text] [Related]
16. Immunological parameters during treatment with ditiocarb (Imuthiol).
Vanham GL; Kestens L; Van Hoof J; Penne G; Colebunders R; Goilav C; Vandenbruaene M; el Habib R; Gigase P
AIDS; 1993 Apr; 7(4):525-30. PubMed ID: 8389559
[TBL] [Abstract][Full Text] [Related]
17. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.
National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group
N Engl J Med; 1991 Jul; 325(2):73-80. PubMed ID: 1675763
[TBL] [Abstract][Full Text] [Related]
19. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.
Pedersen C; Sandström E; Petersen CS; Norkrans G; Gerstoft J; Karlsson A; Christensen KC; Håkansson C; Pehrson PO; Nielsen JO
N Engl J Med; 1990 Jun; 322(25):1757-63. PubMed ID: 1693173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
